[Autom. eng. transl.] As part of the HTA process of Denosumab (Prolia) - a monoclonal antibody capable of inhibiting the activity and development of osteoclasts used in the treatment of osteoporosis - the ethical aspects are analyzed in the light of efficacy, safety and improvement data QoL and economic impact.
|Translated title of the contribution||[Autom. eng. transl.] Denosumab HTA in the prevention of osteoporosis fractures|
|Number of pages||6|
|Journal||Italian Journal of Public Health|
|Volume||2011, vol. 8|
|Publication status||Published - 2011|